Zentalis Pharmaceuticals, Inc.
corporate_fare Company Profile
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for ZNTL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 3 rated 8 or above. Recent SEC coverage for ZNTL spans 8-K, 4, 424B5, DEFA14A.
Recent high-impact activity:
- Zentalis Q3: $228.9M Cash Extends Runway to 1H 2028, DENALI Topline Set for 1H 2027
- Azenosertib OS Separation Confirmed: 15.9 vs 7.5 Months in Cyclin E1-Positive Ovarian Cancer
- Azenosertib Extends Survival to 15.8 Months in Cyclin E1-Positive Ovarian Cancer
- Zentalis' Azenosertib Shows 15.8-Month Median Survival in Cyclin E1-Positive Ovarian Cancer
- Walters Group Buys $15.2M in Zentalis Offering, Stake Rises to 17.8M Shares
Financial Snapshot
Short Interest & Short Volume
3.49 days to coverFINRA reported short interest of 5,036,334 shares in ZNTL as of the October 30, 2026 settlement, a 15.9% decrease from the prior period — about 3.5 days to cover at its recent average daily volume. On November 20, 2026, 46.4% of ZNTL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ZNTL, detected from its recent SEC filings · based on capital-structure filings through 2026-08-14.
Offering Priced at $3.50 · Net Proceeds $75.1M
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →